Anthony Caggiano, the Chief Medical Officer at Cognition Therapeutics Inc. (NASDAQ: CGTX), made a direct purchase of common stock in the company on April 16, 2026. The transaction consisted of 10,000 shares acquired at $1.11 per share, producing a total outlay of $11,100.
Following the purchase, Mr. Caggiano directly holds 874,906 shares of Cognition Therapeutics common stock. The timing of the acquisition coincides with recent strength in the share price - the stock returned 22% over the prior week and has climbed 220% over the past year.
Market valuation commentary in public research notes indicates that, according to InvestingPro analysis, the stock is currently trading above its Fair Value. The research offering also advertises Pro Research Reports available for CGTX and more than 1,400 other U.S. equities for investors seeking more detailed coverage and valuation context.
On the corporate results front, Cognition Therapeutics reported its fourth-quarter 2025 earnings and full-year figures, highlighting a reduction in its net loss. The company posted a net loss of $23.5 million for the year, a 30.9% improvement compared with the prior year. The company described this narrowing of losses as an indication of improved operational efficiency.
In parallel with its financial update, Cognition Therapeutics outlined plans to advance its investigational drug, zervimesine, for treatment of psychosis in dementia with Lewy bodies. The company intends to meet with the U.S. Food and Drug Administration’s Division of Psychiatry in the second quarter of 2026 to discuss a registrational plan for the therapy. That regulatory engagement follows results from the Phase 2 SHIMMER trial, which demonstrated effects on neuropsychiatric inventory measurements.
These developments together - insider buying, a narrower annual net loss, and scheduled regulatory discussions for zervimesine - reflect Cognition Therapeutics’ concurrent focus on financial management and clinical development. The company’s next steps will include the planned dialogue with the FDA around its registrational approach for the drug candidate.
Quick facts
- Insider purchase: 10,000 shares on April 16, 2026 at $1.11 per share, totaling $11,100.
- Post-transaction direct holdings for Anthony Caggiano: 874,906 shares.
- Company performance note: net loss of $23.5 million for 2025, a 30.9% improvement year-over-year.
- Clinical/regulatory: planned meeting with FDA Division of Psychiatry in Q2 2026 regarding registrational plan for zervimesine following Phase 2 SHIMMER results.